立体定向体部放疗治疗肺尖部肿瘤:臂丛剂量学分析与初步临床结果
本研究回顾性分析了2009至2018年78例连续患者共81个T1-3N0非小细胞肺癌肺尖部肿瘤接受立体定向体部放疗(SBRT)的经验,按RTOG图谱勾画臂丛,评估臂丛损伤(BPI)发生率并应用正常组织并发症概率模型分析剂量学数据。5例(6.4%)出现符合BPI的神经症状,中位发生时间11.9个月,BP Dmax(EQD23 Gy)阈值20 Gy时模型曲线下面积0.75(比值比7.3;95%CI 0.8-68.3)。作者认为肺尖部肿瘤SBRT中臂丛受量变异显著,BPI发生率可观,应以前瞻性临床相关性结合剂量学信息制定循证剂量限制。
要点
- 78例患者81个肺尖部肿瘤接受SBRT,5例(6.4%)出现符合臂丛损伤的神经症状,中位发生时间11.9个月。
- 出现BPI者最常见剂量分割为50 Gy分5次(4例),症状包括疼痛2例(40.0%)、手或腋窝麻木4例(80.0%)、同侧手无力1例(20.0%)。
- 总体队列BP Dmax(EQD23 Gy)中位5.13 Gy(范围0.18-217.2 Gy),BPI患者中位32.14 Gy(范围13.4-99.9 Gy);Dmax阈值20 Gy时AUC 0.75(OR 7.3;95%CI 0.8-68.3)。
核心结论
- 肺尖部肿瘤SBRT中臂丛受量存在显著变异,SBRT后神经症状发生率可观,应以前瞻性临床相关性结合剂量学信息制定循证剂量限制。
研究设计与样本
- 2009年至2018年间连续纳入78例患者共81个T1-3N0非小细胞肺癌肺尖部肿瘤(肿瘤中心位于主动脉弓上方)接受SBRT,按RTOG图谱解剖勾画臂丛。
- 回顾性查阅病历以确定臂丛损伤发生率,并对剂量学数据应用正常组织并发症概率模型。
主要发现
- 5例患者(6.4%)报告符合臂丛损伤的神经症状,中位发生于治疗后11.9个月(范围5.2-28.1个月)。
- 出现BPI者中最常见剂量分割为50 Gy分5次(4例);症状为疼痛2例(40.0%)、手或腋窝麻木4例(80.0%)、同侧手无力1例(20.0%)。
- 总体队列BP Dmax(EQD23 Gy)中位5.13 Gy(范围0.18-217.2 Gy),BPI患者中位BP Dmax(EQD23 Gy)32.14 Gy(范围13.4-99.9 Gy)。
- 正常组织并发症概率模型拟合良好,BP Dmax(EQD23 Gy)阈值20 Gy时曲线下面积0.75(比值比7.3;95%置信区间0.8-68.3)。
临床怎么用
- 原文结论指出应以前瞻性临床相关性结合剂量学信息来制定循证剂量限制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dosimetric constraints of the brachial plexus have not yet been well-established for patients undergoing stereotactic body radiation therapy (SBRT). This study evaluated long-term experience with the treatment of early-stage apical lung tumors with SBRT and reports on dosimetric correlates of outcome. METHODS AND MATERIALS: Between 2009 and 2018, a total of 78 consecutive patients with 81 apical lung tumors underwent SBRT for T1-3N0 non-small cell lung cancer. Apical tumors were those with tumor epicenter superior to the aortic arch. The brachial plexus (BP) was anatomically contoured according to the Radiation Therapy Oncology Group atlas. Patient medical records were reviewed retrospectively to determine incidence of brachial plexus injury (BPI) and a normal tissue complication probability model was applied to the dosimetric data. RESULTS: Five patients (6.4%) reported neuropathic symptoms consistent with BPI and occurred a median 11.9 months after treatment (range, 5.2-28.1 months). Most common dose and fractionation in those developing BPI were 50 Gy in 5 fractions (4 patients). Symptoms consisted of pain in 2 patients (40.0%), numbness in the hand or axilla in 4 patients (80.0%), and ipsilateral hand weakness in 1 patient (20.0%). In the overall cohort the median BP Dmax (EQD23 Gy) was 5.13 Gy (range, 0.18-217.2 Gy) and in patients with BPI the median BP Dmax (EQD23 Gy) was 32.14 Gy (range, 13.4-99.9 Gy). The normal tissue complication probability model gave good fit with an area under the curve of 0.75 (odds ratio, 7.3; 95% confidence interval, 0.8-68.3) for BP Dmax (EQD23 Gy) threshold of 20 Gy. CONCLUSIONS: Significant variation exists in the dose delivered to the brachial plexus for patients treated by SBRT for apical lung tumors. The incidence of neuropathic symptoms in the post-SBRT setting was appreciable and prospective clinical correlation with dosimetric information should be used to develop evidence-based dose constraints.
引用
- Morse RT, Doke K, Ganju RG, et al. Stereotactic Body Radiation Therapy for Apical Lung Tumors: Dosimetric Analysis of the Brachial Plexus and Preliminary Clinical Outcomes. Pract Radiat Oncol. 2021. PMID: 34929402. doi:10.1016/j.prro.2021.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。